Dalmora, M. E.Dalmora, S. L.Oliveira, Anselmo Gomes de [UNESP]2014-05-202014-05-202001-07-03International Journal of Pharmaceutics. Amsterdam: Elsevier B.V., v. 222, n. 1, p. 45-55, 2001.0378-5173http://hdl.handle.net/11449/7543Topical formulations of piroxicam were evaluated by determination of their in vitro release and in vivo anti-inflammatory effect. The in vitro release assay demonstrated that the microemulsion (ME) systems provided a reservoir effect for piroxicam release. However, the incorporation of the ME into carboxyvinilic gel provoked a greater reduction in the release of piroxicam than the ME system alone. Anti-inflammatory activity was carried out by the cotton pellet granuloma inhibition bioassay. Topical anti-inflammatory effect of the piroxicam inclusion complex/ME contained in carboxyvinilic gel showed significant inhibition of the inflammation process (36.9%, P < 0.05). Subcutaneous administration of the drug formulations showed a significant effect on the inhibition of inflammation, 68.8 and 70.5%, P <0.05, when the piroxicam was incorporated in ME and in the combined system beta -cyclodextrin (B-CD)/ME, respectively, relative to the buffered piroxicam (42.2%). These results demonstrated that the ME induced prolonged effects, providing inhibition of the inflammation for 9 days after a single dose administration. (C) 2001 Elsevier B.V. B.V. All rights reserved.45-55engpiroxicambeta-cyclodextrinmicroemulsionanti-inflammatory effectin vitro drug releaseArtigo10.1016/S0378-5173(01)00692-5WOS:000169704300005Acesso restrito9114495952533044